Jane Street’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Jane Street’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-45,600	Closed	-$3.7M	–	10284
2021 Q4	$3.7M	Buy	45,600 +38,300	+525%	+$3.28M	﹤0.01%	3343
2021 Q3	$693K	Sell	7,300 -29,100	-80%	-$2.94M	﹤0.01%	6656
2021 Q2	$3.59M	Sell	36,400 -7,800	-18%	-$681K	﹤0.01%	3235
2021 Q1	$3.7M	Sell	44,200 -11,300	-20%	-$1.07M	﹤0.01%	2874
2020 Q4	$4.79M	Sell	55,500 -4,000	-7%	-$310K	﹤0.01%	2182
2020 Q3	$4.16M	Sell	59,500 -1,300	-2%	-$92.2K	﹤0.01%	2054
2020 Q2	$4.41M	Buy	60,800 +47,300	+350%	+$3.02M	﹤0.01%	2005
2020 Q1	$625K	Sell	13,500 -9,700	-42%	-$540K	﹤0.01%	3377
2019 Q4	$1.43M	Buy	23,200 +14,700	+173%	+$784K	﹤0.01%	2323
2019 Q3	$362K	Buy	8,500 +4,400	+107%	+$209K	﹤0.01%	3943
2019 Q2	$213K	Sell	4,100 -31,000	-88%	-$1.54M	﹤0.01%	4623
2019 Q1	$1.95M	Sell	35,100 -61,700	-64%	-$3.32M	﹤0.01%	2057
2018 Q4	$4.07M	Sell	96,800 -44,100	-31%	-$2.3M	0.01%	1081
2018 Q3	$9.81M	Buy	140,900 +124,500	+759%	+$8.14M	0.02%	624
2018 Q2	$938K	Sell	16,400 -89,200	-84%	-$4.86M	﹤0.01%	2824
2018 Q1	$5.81M	Buy	105,600 +88,100	+503%	+$5.28M	0.02%	862
2017 Q4	$981K	Sell	17,500 -1,000	-5%	-$56.4K	﹤0.01%	2367
2017 Q3	$1.13M	Sell	18,500 -18,100	-49%	-$1.03M	﹤0.01%	2168
2017 Q2	$1.95M	Buy	36,600 +18,000	+97%	+$878K	0.01%	1521
2017 Q1	$898K	Buy	18,600 +3,600	+24%	+$167K	﹤0.01%	2182
2016 Q4	$599K	Sell	15,000 -67,800	-82%	-$2.9M	﹤0.01%	2648
2016 Q3	$4.01M	Sell	82,800 -396,100	-83%	-$18.8M	0.02%	715
2016 Q2	$18.6M	Sell	478,900 -19,700	-4%	-$850K	0.09%	204
2016 Q1	$20.4M	Buy	498,600 +140,000	+39%	+$6.19M	0.11%	163
2015 Q4	$25.6M	Buy	358,600 +7,400	+2%	+$494K	0.16%	111
2015 Q3	$20.5M	Buy	351,200 +345,500	+6,061%	+$29.4M	0.13%	127
2015 Q2	$515K	Sell	5,700 -3,500	-38%	-$301K	﹤0.01%	2260
2015 Q1	$729K	Buy	9,200 +400	+5%	+$29.7K	0.01%	1665
2014 Q4	$552K	Sell	8,800 -30,000	-77%	-$1.76M	﹤0.01%	1406
2014 Q3	$2.02M	Sell	38,800 -15,200	-28%	-$737K	0.02%	582
2014 Q2	$2.51M	Sell	54,000 -37,000	-41%	-$1.46M	0.03%	452
2014 Q1	$3.63M	Buy	+91,000	New	+$4.13M	0.04%	332

Other funds holding BIB

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CIA

Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return

CIC

Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

WWM

Westwood Wealth Management Los Angeles, California $255M AUM 54.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CCWM

Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

CWM

Crowley Wealth Management Wilmington, Delaware $126M AUM 23.04% 1-Year Est. Return

Jane Street's BIB Position: Q4 2024 in Review

Jane Street sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2024, closing a stake of 4,803 shares — an estimated $306K sold.

Jane Street first reported a position in BIB in Q4 2013 and held it in 27 quarters. The position peaked at $5.4M in Q1 2015. 24 funds tracked by Wall St. Rank hold BIB as of Q4 2024.

Jane Street reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2024 after selling out during the quarter.
Jane Street sold 4,803 ProShares Ultra NASDAQ Biotechnology shares in Q4 2024, an estimated $306K.
Jane Street first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2013 and held it in 27 quarters.
Jane Street's ProShares Ultra NASDAQ Biotechnology position peaked at $5.4M in Q1 2015.
24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2024.

Based on Jane Street's 13F filing for Q4 2024, filed 14 Feb 2025.